Sanofi Tzield FDA Approves Label Expansion for Younger Children FDA approved Tzield label expansion. Children as young as one year eligible. Delays Stage 3 Type 1 Diabetes. Expands patient population . Sanofi's Tzield (teplizumab-mzwv) received FDA approval for a label expansion. This allows its use in children aged one year and older. The drug targets individuals diagnosed with Stage 2 Type 1 Diabetes (T1D). This approval aims to delay the onset of Stage 3 T1D. The decision follows compelling data demonstrating efficacy in this younger cohort, reinforcing its preventative role. This FDA approval signifies a critical regulatory milestone under 21 CFR Part 314. The agency's decision reflects a favorable benefit-risk profile for early intervention. Sanofi will now update prescribing information and engage healthcare providers. The EMA has not yet announced a similar label expansion for Tzield in Europe. An EMA decision is anticipated within the next 12-18 months. This expansion solidifies Tzield's market position as the sole disease-modifying T1D therapy. Competitors like Provention Bio (acquired by Sanofi) and Eli Lilly lack similar early-stage approvals. This move broadens Sanofi's commercial reach. The expanded indication establishes Tzield as a potential standard of care for at-risk children from April 29, 2026.